Currently, four monoclonal antibodies targeting PD-1 (pembrolizumab and nivolumab) and PD-L1 (atezolizumab and durvalumab) have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.